Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
N Engl J Med. 2019.
PMID: 31851799
Clinical Trial.